| Barchart Demo Center |
$2,41
+0,07 (+2,77%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 2,41 |
|---|---|
| Variation | +0,07 (+2,77%) |
| Ouverture | 2,37 |
| Clôture précédente | 2,35 |
| Écart (actuel) |
2,34
2,50
|
| Écart 52 semaines |
1,35
3,87
|
| Volume | 233 300 |
| Volume Moyen | 382 795 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| SCYX |
 +2,77% |
 +71,28% |
 -8,52% |
| DJIA |
+1,51% |
-2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | 2,04 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | 1,18 |
| Market Capitalization, $K | 83 490 |
| Alpha pondéré | -3,92 |
| Écart-type | +0,43 |
| Marge d'exploitation | 72,18% |
| Beta | 1,49 |
Taux de croissance
| Cette année | +8,30% | |||
| 1 An(s) | -3,01% | |||
| 3 An(s) | -69,96% | |||
| 5 An(s) | -79,36% | |||
| 10 An(s) | -97,13% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Scynexis: Q1 Earnings Snapshot
AP - Wed May 08, 03:50PM CDT
Scynexis: Q1 Earnings Snapshot(version intégrale)
SCYX: 2,41 (+0,07)
SCYNEXIS Reports First Quarter 2024 Financial
GlobeNewswire - Wed May 08, 03:30PM CDT
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the...(version intégrale)
SCYX: 2,41 (+0,07)
SCYNEXIS Presented Preclinical Data on Second
GlobeNewswire - Tue Apr 30, 03:05PM CDT
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a...(version intégrale)
SCYX: 2,41 (+0,07)
SCYNEXIS to Present Preclinical Data on Second
GlobeNewswire - Tue Apr 09, 03:05PM CDT
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...(version intégrale)
SCYX: 2,41 (+0,07)
SCYNEXIS Reports Full Year 2023 Financial
GlobeNewswire - Thu Mar 28, 03:01PM CDT
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study...(version intégrale)
SCYX: 2,41 (+0,07)